At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Healsea Babykids +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Healsea® Babykids in the Treatment of Acute Infectious Rhinitis Symptoms in Children
In Brief
A clinical study evaluating Healsea Babykids and Placebo for Common Cold and Rhinitis Viral. Completed, enrolled 200 participants across 3 sites.
Detailed Summary
The purpose of this post market clinical investigation is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo in children above 2 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold, Rhinitis Viral
CountriesBulgaria
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartFeb 2023
First PostedApr 2023
Primary CompletionMay 2023
TodayJul 2026
First PostedApr 19, 2023
Enrollment StartFeb 13, 2023
Primary CompletionMay 16, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.2 years ago
Interventions
Healsea Babykidsdevice
7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
Placebodevice
7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .